RecruitingNCT07243132

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (LUNGEVITY STUDY)


Sponsor

GFPC Investigation

Enrollment

1,000 participants

Start Date

Jul 2, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study, called the Lungevity Study, is exploring why some people with advanced lung cancer (stage III or IV) survive more than three years — an unusually long time. Researchers want to understand what factors (biological, treatment-related, or personal) contribute to long-term survival, to improve care for all lung cancer patients. **You may be eligible if...** - You are over 18 years old - You have stage III or stage IV non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) - You have been living more than 3 years since your diagnosis - You are NOT currently receiving cytotoxic chemotherapy (you may be on immunotherapy, targeted therapy, or surveillance) - You are covered by the French National Health Insurance **You may NOT be eligible if...** - You have difficulty understanding French - You are currently receiving cytotoxic chemotherapy - You are under legal guardianship or have insufficient cognitive capacity - You refuse to allow your data to be collected Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALHospital Anxiety and Depression scale (HAD)

The HAD scale is an instrument used to screen for anxiety and depressive disorders. It comprises 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to depression (total D), giving two scores (maximum score for each = 21).

BEHAVIORALQuality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)

The EORTC QLQ-LC13: a 13-item lung cancer-specific questionnaire module supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. The QLQ-LC13 includes questions assessing lung cancer-associated symptoms (cough, haemoptysis, dyspnoea and site specific pain), treatment-related side effects (sore mouth, dysphagia, peripheral neuropathy and alopecia) and pain medication.

BEHAVIORALQuestionnaire Aix-Marseille-Université (AMU)

Data analysis will be firstly descriptive in order to report on the quality of life of respondents. Then, in a second stage, the factors associated with quality of life will be analyzed using linear or logistic regression models depending on the nature of the variable of interest.


Locations(46)

CH du Pays d Aix

Aix-en-Provence, France

CHU Angers

Angers, France

Hôpital Henri Duffaut

Avignon, France

CH Bastia

Bastia, France

APHP Hôpital Avicennes

Bobigny, France

CHU Morvan

Brest, France

Hôpital Louis Pradel

Bron, France

Pneumologie Centre François Baclesse

Caen, France

Centre Hospitalier du Cotentin

Cherbourg, France

CHU Hôpital Montpied

Clermont-Ferrand, France

Oncologie CLCC Jean Perrin

Clermont-Ferrand, France

Pneumologie Hospices Civils de Colmar

Colmar, France

Pneumologie Centre Hospitalier Intercommunal de Créteil

Créteil, France

Centre Hospitalier d'Elbeuf - Pneumologie

Elbeuf, France

CH Eure-Seine

Évreux, France

Grand Hôpital de l'Est Francilien - Site Marne la Vallée

Jossigny, France

Centre Hospitalier Les Oudairies

La Roche-sur-Yon, France

CH La Rochelle

La Rochelle, France

Hôpital Robert Boulin

Libourne, France

Hôpital de la Vallée

Longjumeau, France

Hôpital du Scorff

Lorient, France

Pneumologie Hôpital privé Jean Mermoz

Lyon, France

Centre Léon Bérard

Lyon, France

Hôpital Européen

Marseille, France

Hôpital Nord - Oncologie Thoracique

Marseille, France

GHEF Site de Meaux

Meaux, France

CHRU de Nancy

Nancy, France

CHU Nantes

Nantes, France

Pneumologie Hôpital Cochin

Paris, France

Hôpital Tenon

Paris, France

Hôpital La Pitié-Salpêtrière

Paris, France

Pneumologie Centre Hospitalier

Pau, France

Centre Catalan d'Oncologie

Perpignan, France

CHU Reims Hôpital Maison Blanche

Reims, France

CHU Hôpital Ponchailloux

Rennes, France

Hôpital Charles Nicolle

Rouen, France

Hôpital Privé de la Loire

Saint-Etienne, France

Pneumologie CHU St Etienne

Saint-Etienne, France

CH des Vallées de l'Ariège

Saint-Jean-de-Verges, France

CHU La Réunion Site Sud

Saint-Pierre, France

CHU La Réunion Site Sud

Saint-Pierre, France

CH de Saint Malo

St-Malo, France

Hôpital d'Instruction des Armées Saint-Anne

Toulon, France

Hôpital Larrey

Toulouse, France

Oncologie CH Bretagne-Atlantique

Vannes, France

Centre Hospitalier de Villefranche sur Saone

Villefranche-sur-Saône, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07243132


Related Trials